P62 as a diagnostic tool for alzheimer's disease
The p62 protein has been analyzed and identified as the significant contributor to several metabolic pathways that lead to metabolic syndrome, Alzheimer's Disease, and other related diseases. The absence of the p62 protein has a profound effect on the accumulation of tau protein, amyloid beta protein and an increase in blood insulin levels. The accumulation of tau protein and amyloid beta protein in neurological tissues is a hallmark of neurological metabolic diseases such as Alzheimer's Disease and related dementias. Moreover, increase blood insulin levels is an indicator of insulin resistance in mammals. Accordingly, the present invention provides a method for screening a mammal for metabolic disease comprising the step of detecting the absence of the p62 protein. The present invention also contemplates a method of screening a mammal for a metabolic syndrome comprising the steps of detecting the level of p62 protein in a metabolic pathway and determining whether the level of p62 protein falls below a threshold level. A pharmaceutical composition is also contemplated for therapeutic supplementation of a metabolic pathway, the pharmaceutical composition comprising a p62 protein or an amide, ester or salt thereof and a pharmaceutically effective carrier. Such pharmaceutical composition will have an inhibitory action on the phosphorylation, ubiquitination, accumulation of tau protein, an inhibitory effect on the accumulation of APP/amyloid beta and may operate to lower blood insulin levels.
1. A method of screening a human for Alzheimer's disease comprising the steps of:
obtaining a cortical brain tissue sample from a subject;
measuring the amount of p62 protein in the sample; and
comparing the measured amount of p62 protein against a control amount of p62 protein from a control brain tissue sample of a non-affected subject;
wherein Alzheimer's disease is identified when the measured amount of p62 protein is fifty percent or less than the amount of p62 protein in the control sample.
2. The method of claim 1 , wherein the brain tissue sample is a cortical brain tissue homogenate.
3. The method of claim 1 , wherein the comparing step further comprises:
obtaining a control brain tissue sample from a subject not affected with Alzheimer's disease; and
measuring a control amount of p62 protein from the control brain tissue sample.